Most Read Articles
Pearl Toh, 27 Mar 2020
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 6 days ago
Treatment with hydroxychloroquine appears to significantly reduce viral load in patients with the novel coronavirus disease (COVID-19), with its beneficial effects reinforced by adding azithromycin, results of a recent study have shown.
Elvira Manzano, 22 Nov 2017
A blood pressure (BP) reading of 130/80 mm Hg or higher is the ‘new high’ in the latest AHA/ACC* hypertension guidelines, a threshold that is tighter than the JNC 7** cutpoint of 140/90 mm Hg for stage 1 hypertension in the general population. The change will mean more patients being labelled with hypertension.
Audrey Abella, 27 Mar 2020
The angiotensin receptor blocker (ARB) losartan did not improve inflammation, T-cell immune recovery, or fibrotic activity among older persons living with HIV (PLHIV) and viral suppression, according to data presented at CROI 2020.

Adalimumab biosimilar noninferior to reference product for Crohn’s disease

Pearl Toh
16 Jan 2020

The adalimumab biosimilar BI 695501 shows similar efficacy and safety profile as its reference product in patients with moderate-to-severe Crohn's disease (CD), according to a phase III study recently presented at the Advances in Inflammatory Bowel Diseases (AIBD) 2019 Conference.

While BI 695501 was previously shown to be bioequivalent to the adalimumab reference product for rheumatoid arthritis, it has not been specifically tested in patients with CD. The current study represents the first randomized trial to do so for the indication of CD, said lead investigator Dr Stephen Hanauer from Northwestern University in Chicago, Illinois, US.

“In a primary analysis based on efficacy data up to week 4, BI 695501 demonstrated noninferior efficacy compared with adalimumab reference product in patients with active CD,” he reported.

At 4 weeks, the primary endpoint of CD Activity Index (CDAI) response, defined as a 70-point decreased score, occurred in similar proportion of patients in the biosimilar and the adalimumab groups (89.7 percent vs 94.4 percent). The corresponding relative risk (RR) was 0.945 (95 percent confidence interval [CI], 0.856–1.044), thus meeting the criteria for the exploratory noninferiority margin. [AIBD 2019, abstract P052]

The per-protocol analysis also showed similar rates of CDAI response between the two groups (RR, 0.941, 95 percent CI, 0.859–1.030), consistent with the results of the primary analysis. 

In addition, treatment effects were comparable between both groups in terms of improvements of ≥100 points in CDAI scores and absolute CDAI scores of <150 during the induction phase.  

“Moreover, safety profiles up to 24 weeks were similar between treatment arms,” observed Hanauer.

There were no significant differences in the incidence of adverse events (AEs) of any grade (41.7 percent vs 36.0 percent) and serious AEs (2.8 percent vs 4.0 percent) with no unexpected safety signals at 24 weeks.

AEs of special interest were uncommon in both groups (1.4 percent vs 2.7 percent). Specifically, infection rates were similar, reported in 13.9 percent of the patients receiving the biosimilar and 14.7 percent of those on adalimumab. Injection site reactions occurred more frequently with adalimumab (4.0 percent) compared with none in the biosimilar group.  

The phase III, double-blind, multicentre, noninferiority trial involved 147 patients with active CD who were randomized 1:1 to receive the biosimilar BI 695501 or the reference EU-approved adalimumab with the following dosing regimen: loading dose of 160 mg on day 1, 80 mg on day 15, followed by 40 mg every 2 weeks subsequently. Those who showed response to treatment after 4 weeks continued on maintenance therapy up till 24 weeks, at which point patients receiving the adalimumab reference product were switched to BI 695501.

Patients were stratified according to whether they had previous exposure to infliximab and baseline Simple Endoscopic Score for CD. Both groups were balanced in terms of baseline characteristics. In general, the population showed high response and remission rates.  

According to Hanauer, the finding that BI 695501 was noninferior to adalimumab specifically in CD would allow for less costly treatment options for CD patients. 

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 27 Mar 2020
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 6 days ago
Treatment with hydroxychloroquine appears to significantly reduce viral load in patients with the novel coronavirus disease (COVID-19), with its beneficial effects reinforced by adding azithromycin, results of a recent study have shown.
Elvira Manzano, 22 Nov 2017
A blood pressure (BP) reading of 130/80 mm Hg or higher is the ‘new high’ in the latest AHA/ACC* hypertension guidelines, a threshold that is tighter than the JNC 7** cutpoint of 140/90 mm Hg for stage 1 hypertension in the general population. The change will mean more patients being labelled with hypertension.
Audrey Abella, 27 Mar 2020
The angiotensin receptor blocker (ARB) losartan did not improve inflammation, T-cell immune recovery, or fibrotic activity among older persons living with HIV (PLHIV) and viral suppression, according to data presented at CROI 2020.